Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gentamicin/vancomycin - Dr Reddys Laboratories

Drug Profile

Gentamicin/vancomycin - Dr Reddys Laboratories

Alternative Names: DFA-02; Vancomycin/gentamicin; Ximycin

Latest Information Update: 10 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dr Reddys Laboratories; Duke Clinical Research Institute
  • Class Aminoglycosides; Antibacterials; Glycopeptides; Peptide antibiotics; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Postoperative infections

Most Recent Events

  • 01 Oct 2018 Dr. Reddy’s Laboratories regains worldwide rights of gentamicin/vancomycin gel from Armis Biopharma for Postoperative infections
  • 07 Feb 2018 Armis Biopharma has patent protection for gentamicin/vancomycin
  • 29 Jan 2018 Armis Biopharma plans a phase III registration trial for Postoperative infections (Surgical site infections) (Prevention) in first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top